Overall Survival Rate Nearly100%! Johnson & Johnson Announces Impressive Results of Breakthrough Therapy

Recently, Johnson & Johnson (Johnson & Johnson) Announced2bPeriodSunRISe-1Study No.4Cohort (Cohort 4) with positive results, which evaluated its innovative intravesical drug delivery systemTAR-200Efficacy in specific types of bladder cancer patients. Preliminary results show,TAR-200In BCG (BCG) Non-responsive high-risk non-muscle-invasive bladder cancer (HR-NMIBC) of patients, their disease-free survival rate (DFS) Exceed80%`, and`94%Patients are able to retain their bladder and do not require re-induction treatment.TAR-200In maintaining patients' highDFSWhile preserving the bladder, it also demonstrates good safety, showing its potential to become a meaningful treatment option beyond surgery. In addition,TAR-200The early progression-free survival rate and overall survival rate of the group at nine months were95.6%And98%`, indicating acceptance`TAR-200Among the treated patients, disease progression or death was very rare.These results support continued3PeriodSunRISe-5Continued evaluation in the studyTAR-200, This study evaluatesTAR-200Compared with chemotherapy, afterBCGPreprocessing, with only papillary lesionsHR-NMIBCEfficacy and safety in patients.

TAR-200It is an investigational intravesical drug delivery system designed to achieve sustained local release of gemcitabine in the bladder, maintaining local drug exposure for up to several weeks.The system is implanted in the bladder by medical professionals through a配套的尿道放置导管 in an outpatient setting, taking less than five minutes without anesthesia.2023Year12Month, USAFDAGrantTAR-200Breakthrough Therapy Designation (BTD), used to treat patients who are not suitable for or choose not to undergo radical cystectomy, forBCGPatients with high-risk non-muscle-invasive bladder cancer and carcinoma in situ who do not respond to treatment.

For the first time! Super80%Complete Disappearance of Tumors in Cancer PatientsGSKImmunotherapy Featured in The New England Journal of Medicine

Recently,GSKIn2025American Association for Cancer Research (AACR) was announced at the annual meeting, itsPD-1InhibitorJemperli（dostarlimab) in2In the clinical trial period, used for treatmentMismatch Repair Deficiency (dMMR) Eye-catching results for cancer patients. The analysis shows,After receiving six months of monotherapyAfter treatment with dostarlimab,80%Patients do not need to undergo surgery, radiotherapy, or chemotherapy.This result was simultaneously published in The New England Journal of Medicine.According to the press release, this is the first study to show that immunotherapy can replace surgical treatment for various solid tumors.

A total of117Number of patients. On the1In the cohort, all treatments completed49All patients achieved clinical complete remission and opted to continue with non-surgical management. Among them,37Patients after treatment12months maintained clinical complete remission, meeting the efficacy evaluation criteria. In the2In the queue,54Among the patients who have completed treatment35The name achieved complete clinical remission, and among them33The patient chose to continue with non-surgical management.

In two cohorts combined103Among the patients who have completed treatment(IncludingIToIIIPatients with advanced cancer, including49The case is a patient with rectal cancer,54The cases were non-rectal cancer patients, covering gastroesophageal, hepatobiliary, colon, genitourinary, and gynecological tumors.)Total84Name achieved clinical complete remission (81.6%），82# RoleYou are an expert who can translate Chinese into English.# Skill1. You are proficient in both Chinese and English.2. You can ensure the accuracy and authority of the translation.3. You are familiar with the medical industry and professional vocabulary.# Text117In the total patient population, the two-year recurrence-free survival rate was92%（95% CI：86-99）。Most patients (95%) Reversible1Level or2Grade Adverse Event (60%），35% did not experience adverse events. The patients' opportunity to undergo radical resection surgery was not affected during or after the treatment.

20For the first time in many years!KeytrudaCombination Therapy3Positive Results Announced

Recently, Merck (MSD) announced3PeriodKEYNOTE-689The results of the trial, which evaluatedPD-1InhibitorKeytruda（pembrolizumab) as a perioperative treatment regimen for stage III or IVAPeriod, resectable locally advanced squamous cell carcinoma of the head and neck (LA-HNSCC) in patients. The first interim analysis showed that, with standard care (SOC) Radiotherapy (with or without cisplatin) as an adjunct to adjuvant therapy,KeytrudaAs part of perioperative treatment, it significantly improved event-free survival in patients compared to those receiving standard care radiation therapy alone (with or without cisplatin).EFS). According to the press release,KEYNOTE-689Become20The first in many years inLA-HNSCCClinical trials achieving positive results in patients who had undergone surgical tumor removal.

The analysis showed that, at a median follow-up time of38.3Months (Range:9.0-66.5months) when, inCPS≥10Among the crowd,KeytrudaMedian of the Combined Standard Care GroupEFSFor59.7Months (95%CI：41.1-Not reached), while the standard care group was26.9Months (95% CI：18.3-51.5）。InCPS≥1Among the crowd,KeytrudaMedian of the Combined Standard Care GroupEFSFor59.7Months (95% CI：37.9-Not reached), while the standard care group was29.6Months (95% CI：19.5-41.9). In the intention-to-treat (ITT) In the population,KeytrudaMedian of the Combined Standard Care GroupEFSFor51.8Months (95% CI：37.5-Not reached), while the standard care group was30.4Months (95% CI：21.8-50.1）。KeytrudaThe safety profile was consistent with previously reported studies, and no new safety signals were identified.

[1] Johnson & Johnson’s TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC. Retrieved April 28, 2025 from https://www.prnewswire.com/news-releases/johnson--johnsons-tar-200-monotherapy-achieves-high-disease-free-survival-of-more-than-80-percent-in-bcg-unresponsive-high-risk-papillary-nmibc-302438971.html

[2] KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma. Retrieved April 28, 2025 from https://www.merck.com/news/keytruda-pembrolizumab-as-perioperative-treatment-with-standard-of-care-soc-adjuvant-therapy-significantly-improved-event-free-survival-compared-to-soc-alone-in-patients-with-resectable-loca/

[3] Immunotherapy Could Replace Surgery, Enabling Patients To Retain Their Organs and Enhance Their Quality of Life. Retrieved April 28, 2025 from https://www.mskcc.org/news-releases/immunotherapy-could-replace-surgery-enabling-patients-to-retain-their-organs-and-enhance-their-quality-of-life

[4] Cercek A, Foote MB, Rousseau B, Smith JJ, Shia J, Sinopoli J, Weiss J, Lumish M, Temple L, Patel M, Wilde C, Saltz LB, Argiles G, Stadler Z, Artz O, Maron S, Ku G, Gu P, Janjigian YY, Molena D, Iyer G, Coleman J, Abida W, Cohen S, Soares K, Schattner M, Strong VE, Yaeger R, Paty P, Shcherba M, Sugarman R, Romesser PB, Zervoudakis A, Desai A, Segal NH, El Dika I, Widmar M, Wei I, Pappou E, Fumo G, Aparo S, Gonen M, Gollub M, Jayaprakasham VS, Kim TH, Garcia Aguilar J, Weiser M, Diaz LA Jr. Nonoperative Management of Mismatch Repair-Deficient Tumors. N Engl J Med. 2025 Apr 27. doi: 10.1056/NEJMoa2404512. Epub ahead of print. PMID: 40293177.

Disclaimer: This article is for information exchange purposes only. The views expressed in the article do not represent the position of WuXi AppTec, nor does it imply that WuXi AppTec supports or opposes the views mentioned. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.

Copyright Statement: Individuals are welcome to share this article on their WeChat Moments. Unauthorized reproduction by media or organizations in any form to other platforms is prohibited. For authorization, please reply "Reprint" on the "WuXi AppTec" WeChat Official Account to obtain reprint guidelines.